Literature DB >> 3019986

Treatment of cryptococcal meningitis in mice with fluconazole.

E Palou de Fernandez, M M Patino, J R Graybill, M H Tarbit.   

Abstract

Fluconazole is a recently developed triazole with activity in vitro against Cryptococcus neoformans, water solubility, and excellent oral absorption. We compared fluconazole in murine cryptococcosis with ketoconazole and amphotericin B. Fluconazole was highly effective in suppressing cryptococcosis in mice challenged by the intravenous and intranasal routes, and was comparable with the other two drugs in its protective capacity. However, fluconazole was superior to ketoconazole and comparable with amphotericin B after intracerebral challenge. Fluconazole may warrant clinical evaluation in cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3019986     DOI: 10.1093/jac/18.2.261

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  In vitro and in vivo activities of Sch 39304, fluconazole, and amphotericin B against Histoplasma capsulatum.

Authors:  G S Kobayashi; S J Travis; M G Rinaldi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

Review 2.  Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses.

Authors:  S M Grant; S P Clissold
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

3.  Therapeutic effect of the triazole Bay R 3783 in mouse models of coccidioidomycosis, blastomycosis, and histoplasmosis.

Authors:  D Pappagianis; B L Zimmer; G Theodoropoulos; M Plempel; R F Hector
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

5.  Orally administered antifungal therapy for experimental keratomycosis.

Authors:  D M O'Day
Journal:  Trans Am Ophthalmol Soc       Date:  1990

Review 6.  Current concepts in cryptococcosis.

Authors:  T F Patterson; V T Andriole
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

7.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

8.  Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice.

Authors:  Justina Y Ju; Cynthia Polhamus; Kieren A Marr; Steven M Holland; John E Bennett
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

Review 10.  Fluconazole. Review and situation among antifungal drugs in the treatment of opportunistic mycoses of human immuno-deficiency virus infections.

Authors:  F N Vincent-Ballereau; O N Patey; C Lafaix
Journal:  Pharm Weekbl Sci       Date:  1991-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.